World Pharma News

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 15 min 58 sec ago

Can an antibody 'cocktail' prevent COVID-19 infection?

Tue, 10/13/2020 - 10:00
In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients. The drug was recently administered to President Donald Trump as part of his treatment for SAR-CoV-2 infection. It is still in the clinical experimental stage as potential treatment and prevention for COVID-19.

Gilead Sciences signs joint procurement agreement with the European Commission for Veklury® (remdesivir)

Mon, 10/12/2020 - 12:00
Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU). The JPA enables participating countries in the EU and the European Economic Area (EEA) and the UK to purchase Veklury for both real-time demand and stockpiling needs, coordinated by the European Commission.

Total deaths recorded during the pandemic far exceed those attributed to COVID-19

Mon, 10/12/2020 - 10:00
For every two deaths attributed to COVID-19 in the U.S., a third American dies as a result of the pandemic, according to new data publishing Oct. 12 in the Journal of the American Medical Association.

The study, led by researchers at Virginia Commonwealth University, shows that deaths between March 1 and Aug. 1 increased 20% compared to previous years - maybe not surprising in a pandemic. But deaths attributed to COVID-19 only accounted for 67% of those deaths.

COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials

Fri, 10/09/2020 - 19:00
AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been engineered with AstraZeneca's proprietary half-life extension technology to increase the durability of the therapy for six to 12 months following a single administration.

Potential COVID-19 vaccines not affected by dominant "G-Strain"

Fri, 10/09/2020 - 10:00
Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologist.

Most vaccines under development worldwide have been modelled on the original 'D-strain' of the virus, which were more common amongst sequences published early in the pandemic.

Johnson & Johnson announces European Commission approval of agreement to supply 200 million doses of Janssen's COVID-19 vaccine candidate

Thu, 10/08/2020 - 12:00
Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators.

Protective antibodies persist for months in survivors of serious COVID-19 infections

Thu, 10/08/2020 - 10:00
People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General Hospital (MGH). The study, published in Science Immunology, offers hope that people infected with the virus will develop lasting protection against reinfection.

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

Wed, 10/07/2020 - 12:00
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalisation.

Mask mandates shown to significantly reduce spread of COVID-19

Wed, 10/07/2020 - 10:00
A new study by Simon Fraser University (SFU) researchers has found clear evidence that wearing a mask can have a significant impact on the spread of COVID-19. The researchers, from SFU's Department of Economics, have determined that mask mandates are associated with a 25 per cent or larger weekly reduction in COVID-19 cases.

BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2

Tue, 10/06/2020 - 12:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies' vaccine development program against COVID-19. The EMA's decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults,

Previous infection with other types of coronaviruses may lessen severity of COVID-19

Tue, 10/06/2020 - 10:00
Being previously infected with a coronaviruses that cause the "common cold" may decrease the severity of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infections, according to results of a new study. Led by researchers at Boston Medical Center and Boston University School of Medicine, the study also demonstrates that the immunity built up from previous non-SARS-CoV-2 coronavirus infections does not prevent individuals from getting COVID-19.

CureVac initiates Phase 2a clinical trial of COVID-19 vaccine candidate

Mon, 10/05/2020 - 12:00
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV.

Nitric oxide a possible treatment for COVID-19

Mon, 10/05/2020 - 10:00
Researchers at Uppsala University have found that an effective way of treating the coronavirus behind the 2003 SARS epidemic also works on the closely related SARS-CoV-2 virus, the culprit in the ongoing COVID-19 pandemic. The substance concerned is nitric oxide (NO), a compound with antiviral properties that is produced by the body itself. The study is published in the journal Redox Biology.

New clinical trial for a COVID-19 vaccine authorised in Germany

Fri, 10/02/2020 - 12:00
The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines has authorised another Phase-1 clinical trial of a vaccine against COVID-19 in Germany. The new vaccine candidate is a so-called vector vaccine. Trials on vaccine candidates in humans are a significant step in the direction of authorising safe and efficacious vaccines against COVID-19.

COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India

Fri, 10/02/2020 - 10:00
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

A standard review process triggered a voluntary pause to vaccination across all global trials on 6 September to allow review of safety data by an independent committee.

Researchers call for loss of smell to be recognized globally as a symptom of COVID-19

Thu, 10/01/2020 - 10:00
Four out of five people experiencing the recent loss of smell and/or taste tested positive for COVID-19 antibodies - and of those who tested positive, 40 percent did not have cough or fever, reports a new study in PLOS Medicine by Prof. Rachel Batterham at University College London and colleagues.

Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults

Wed, 09/30/2020 - 12:00
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation

Wed, 09/30/2020 - 10:00
EMA's human medicines committee (CHMP) has completed its review of results from the RECOVERY study arm that involved the use of the corticosteroid medicine dexamethasone in the treatment of patients with COVID-19 admitted to hospital, and has concluded that dexamethasone can be considered a treatment option for patients who require oxygen therapy (from supplemental oxygen to mechanical ventilation).

VirScan offers new insights into COVID-19 antibody response

Tue, 09/29/2020 - 12:00
A tool designed to detect viral history in a drop of blood has gotten an upgrade in the age of COVID-19. VirScan, a technology that can determine which of more than 1,000 different viruses have infected a person, can now also detect evidence of infection from coronaviruses, including SARS-CoV-2.

Researchers uncover clues for COVID-19 treatment

Tue, 09/29/2020 - 10:00
By examining preexisting research for other conditions, researchers at the University of Cincinnati have found a potential treatment that could be applied to COVID-19.

The findings, published in the Journal of Biological Chemistry, established that a lipid found in the human body could be used to prevent or treat infections with SARS-CoV-2, the virus that causes COVID-19.